Compass Therapeutics

CMPX

Biotechnology · Healthcare

Exchange

NASDAQ

Winston Score

Winston is worried

Below-average fundamentals — multiple weak pillars.

Data as of Aug 23, 2026 · filings through Jun 30, 2026

How the score breaks down

Quality

Weak

Growth

Weak

Cash Flow

Weak

Stability

Good

Valuation

Data not available

Track this stock — start free trial

Winston Score History

The full picture

Compass Therapeutics is a small biotechnology company focused on discovering and developing new drugs to treat cancer. Its pipeline centers on therapies that target the immune system, particularly drugs designed to help the body's own defenses fight tumors. The company is in the clinical stage, meaning none of its drugs have been approved for sale yet.

Compass makes no meaningful revenue right now and funds its operations through equity raises and partnerships, which is typical for early-stage biotech firms. It operates primarily in the United States and has a market cap of roughly $300 million. The negative margins reflect heavy spending on research and clinical trials with no product sales to offset costs. The key risk is that the company must successfully advance its drug candidates through clinical trials and eventually win regulatory approval — a process that is expensive, time-consuming, and often fails — before it can generate sustainable revenue.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

+7.1% YoY

YoY Growth Rate

Slow EPS growth

Insider Activity

31.9%ownership

↑ Rising

Insiders increasing their stake — aligned with shareholders

Cash Runway

~3 years

$180M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

$180M cash & investments at current burn rate

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

50.0%

Healthy — 50.0% gross margin

Profit after running costs

Operating Margin

-3665.6%

Losing money on operations — -3665.6%

Return on the money invested

ROCE

-46.2%

Weak — -46.2% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

N/A

Data not available

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

4/8 quarters

Earnings inconsistent quarter-to-quarter

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

—

Data not available

Spare cash per sale

FCF Margin

-7659.6%

Burning cash (-7659.6%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

0.06

Conservative — low debt load (0.06)

Covers its interest

Interest Cover

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

no trend

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial